Glucagon-Like Peptide-1 Receptor Agonists

01/01/2021 - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). "
01/01/2023 - "Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have proven beneficial in type 2 diabetes, are amongst the few medicines approved for weight management, and are also licensed for focused cardiovascular risk reduction. "
01/01/2022 - "In type 2 diabetes patients, Glucagon-like peptide-1 receptor agonists have been shown to improve major cardiac outcomes. "
02/01/2017 - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a mainstay of treatment options for type 2 diabetes. "
01/01/2012 - "GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). "

04/01/2008 - "Only incretin-mimetics have a lowering HbA1c action, due to the improvement in beta-cell function, which is coupled to significant weight loss. "
01/01/2023 - "Weight-loss medications, especially incretin mimetics, are effective for short- and long-term treatment. "
01/10/2012 - "Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials."
01/01/2024 - "Recently, glucagon-like peptide-1 receptor agonists have gained notable popularity within the scientific literature and media for their efficacy in weight loss. "
12/01/2023 - "Considerations on the Weight Loss-Associated Glucagon-like Peptide-1 Receptor Agonists for Older People."

01/01/2021 - "Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. "
01/01/2022 - "Glucagon-like peptide 1 receptor agonists have shown promising results in patients with PCOS and NAFLD, but future randomized trails are needed to confirm this benefit. "
08/01/2020 - "The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials."
08/01/2020 - "The aim of this meta-analysis was to assess the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in patients with NAFLD. "
01/01/2023 - "GLP-1 analogs are currently being extensively studied in clinical trials in the context of NAFLD. "

01/01/2023 - "Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. "
09/01/2021 - "Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis."
12/01/2023 - "As glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been licensed for the treatment of diabetes and obesity, they were one of the first drug types to be evaluated in patients with MASH, and successful phase IIa and IIb studies have resulted in progression to phase III clinical trials. "
01/01/2023 - "Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials."
09/01/2021 - "Web of Science, PubMed/MEDLINE, and Scopus databases from 01/01/1994-01/01/2021 for randomized control trials examining the weight, BMI, cardiometabolic, or gastrointestinal effects of GLP-1 receptor agonists in children and adolescents with obesity. "

11/21/2023 - "Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV?"
02/08/2023 - "Most reports assessed glucagon-like peptide-1 receptor agonists and showed a substantial reduction in body weight. "
01/01/2023 - "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D, and some reduce the risk of cardiovascular (CV) events in those with high CV risk. "
01/01/2022 - "Glucagon-like peptide-1 receptor agonists are associated with reduced appetite and body weight, mediated by direct and indirect central nervous system (CNS) effects. "
01/01/2022 - "Glucagon-like peptide-1 receptor agonists reduce appetite and body weight because of direct and indirect effects on the brain. "